Tagged with Fact

China Rogier Janssens, GM of the Biopharma business of Merck KGaA, Darmstadt, Germany in China, shares the highlights of his first 16 months at the affiliate; the impact of the regulatory changes on the Biopharma business of Merck KGaA, Darmstadt, Germany in China; the significance of the affiliate’s commercial growth as…

Turkey Uğur Bingöl, general manager of Ibrahim Etem Menarini, speaks of his company’s rapid growth and new product lines. He also describes his take on the Turkish pharmaceutical market and outlines his strategic priorities to continue growing Ibrahim Etem Menarini’s presence in Turkey.   We are committed to the localization movement…

Korea Kyungjin Peter Kim, CEO of ST Pharm, provides an insight into his expansion of the company’s operations from simply a CMO into a CDMO and new drug development. He also explains his decision to focus on manufacturing oligonucleotides, the potential in that market, and the challenges to the next objectives.…

Turkey Mehmet Baharoglu and Beril Tezcanli of Birgi Mefar Group, Turkey’s leading CMO with a proven track record and experience of production across all small and medium volume injectable dosage forms for local, international and multinational pharmaceuticals, provide insights into the Group’s unrivalled expertise and competitive advantages as well as its…

Turkey Barış Özyurtlu, general manager of Berko Pharmaceuticals, one of the fastest growing companies in Turkey, provides insights into the company’s innovative vision and proprietary technologies, such as its spoon-shaped product presentation. The latter has already caught the attention of several partners in the US and Canada and should further propel…

Spain Manuel Ramos Ortega, chairman of Labiana, a Spanish CDMO, highlights his strategy to create company stability and discusses the major trends in the manufacturing world of human medicines. Furthermore, he gives an overview of what differentiates Spain and Labiana in the competitive world of pharmaceutical production.   The old business…

Malaysia How Malaysia is setting itself up to provide biosimilars across the Islamic world as well as Asia.   Inno Bio Ventures, a Malaysian state-owned company originally set up to create drug security by ensuring that the country was self-sufficient in terms of medicine supply, has been making its first moves…

Malaysia Tan Sri Rahman Mamat, chairman of Inno Bio Ventures, provides his vision for biosimilars’ potential in Malaysia, and the progress the company has made in laying the foundations to make Malaysia an export hub for biological products in the future.   There is a strong potential for exporting biosimilars [from…

Turkey In 2016 the Turkish Medicine and Medical Devices Agency (TiTCK) implemented a localisation policy to reduce Turkey’s reliance on imports – a few years later, it has created a young, ambitious export sector.   Turkey’s experiment with mandatory localisation policies for pharmaceutical and medical products production is paying off nicely.…

Turkey Ufuk S. Kumrulu, general manager of Polifarma, and Vildan Kumrulu, member of the board, share how the company has strategized its internal investments in recent years and how it plans to take its portfolio into new markets as well as propel the development of its contract manufacturing arm, AIS Pharma.…

Turkey Dr. Altan Demirdere, president of Novartis Group in Turkey discusses the long history of Novartis and Sandoz in the country, as well as the current issues between the Turkish pharmaceutical industry and the government.   Through its Sandoz division, Novartis has been in Turkey since 1930 Can you introduce the…

Europe The latest EFPIA data ranking European countries by the value of their pharmaceutical production. Switzerland is far and away the leader by this measurement, with EUR 46.280 billion-worth of pharma production in 2016, followed by Italy and Germany.